The CRISPR/Cas9 gene editing platform has accelerated vaccine development against infectious diseases. Scientists use CRISPR to improve their understanding of host-virus interactions and viral gene functions, screen for vaccine targets, and act as an antiviral agent. In this webinar brought to you by ERS, Rao Venigalla will discuss a novel approach to vaccine development using CRISPR engineering of bacteriophages.
Topics to be covered
- CRISPR engineering; needle-free SARS-CoV-2 vaccine
- A bacteriophage T4-based, highly efficacious, needle and adjuvant-free, mucosal COVID-19 vaccine
Tuesday, May 31st, 2022 | 2:30 - 3:30 PM Eastern Time
This webinar will be available to view live and on demand.
Speaker
Rao B. Venigalla, PhD
Professor of Biology
Director, Bacteriophage Medical Research Center
The Catholic University of America